Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Development
Merck to buy immune drug firm Pandion for $1.85 billion
by Michael McCoy
February 26, 2021
| A version of this story appeared in
Volume 99, Issue 7
Merck & Co. will acquire Watertown, Massachusetts–based Pandion Therapeutics for $1.85 billion. Pandion was founded in 2017 by biotech veteran Jo Viney and others to engineer immune effector modules to mimic the action of the body’s immune control nodes. Pandion went public in July 2020. The firm describes its lead candidate, PT101, as an engineered interleukin-2 mutein fused to a protein backbone. The molecule is designed to activate and expand regulatory T cells for the treatment of ulcerative colitis and other autoimmune diseases.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X